Activities per year
Activities
- 1 - 50 out of 73 results
Search results
-
Risque thrombotique des oestroprogestatifs
Douxfils, J. (Speaker)
3 Apr 2025Activity: Talk or presentation types › Invited talk
-
Lower reporting of venous thromboembolisms events with natural estrogen-based COCs compared to ethinylestradiol containing pills: A disproportionality analysis of the Eudravigilance database.
Douxfils, J. (Speaker)
22 Mar 2025Activity: Talk or presentation types › Invited talk
-
Towards safer and more responsible use of estrogen-based oral contraceptives
Douxfils, J. (Speaker)
22 Mar 2025Activity: Talk or presentation types › Invited talk
-
Does E4/DRSP have minimal impact on hemostasis and VTE risk? The evidence is growing
Douxfils, J. (Speaker)
20 Mar 2025Activity: Talk or presentation types › Invited talk
-
Risque thrombotique des oestroprogestatifs : quoi de neuf ?
Douxfils, J. (Speaker)
13 Mar 2025Activity: Talk or presentation types › Invited talk
-
Risque thromboembolique veineux de l’add back thérapie
Douxfils, J. (Speaker)
13 Mar 2025Activity: Talk or presentation types › Invited talk
-
Vers une utilisation plus sûre et responsable des contraceptifs oraux à base d'estrogène
Douxfils, J. (Speaker)
11 Feb 2025Activity: Talk or presentation types › Invited talk
-
Navigating new regulations in biobanking for clinical studies and research projects
Douxfils, J. (Speaker)
17 Dec 2024Activity: Talk or presentation types › Invited talk
-
The normalized Activated Protein C sensitivity ratio (nAPCsr): the INR of the gynecologist for a safer prescription of estrogen-containing products
Douxfils, J. (Speaker)
11 Dec 2024Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
20 Jun 2024Activity: Talk or presentation types › Invited talk
-
Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Douxfils, J. (Speaker)
10 Jun 2024Activity: Talk or presentation types › Invited talk
-
Estetrol - an estrogen through life: Cardiovascular impact and the risk of VTE
Douxfils, J. (Speaker)
4 Jun 2024Activity: Talk or presentation types › Invited talk
-
Thromboses associées aux contraceptifs hormonaux combinés: évaluation du risque et suivi thérapeutique par un nouveau test, le nAPCr
Douxfils, J. (Speaker)
27 Jun 2024Activity: Talk or presentation types › Invited talk
-
Is there new data to support the screening of women for hereditary thrombophilia before prescribing pills?
Douxfils, J. (Speaker)
1 May 2024Activity: Talk or presentation types › Invited talk
-
Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using DOAC Dipstick in Various Indications
Harenberg, J. F. (Speaker), Ageno, W. (Speaker), Becattini, C. (Speaker), Douxfils, J. (Speaker), Falanga, A. (Speaker), Hetjens, S. (Speaker), Marchetti, M. (Speaker), Vassart, J. (Speaker), Violi, F. (Speaker), Weiss, C. (Speaker) & Weitz, J. I. (Speaker)
17 May 2024Activity: Talk or presentation types › Invited talk
-
Is there a physiological explanation to VTE risk observed in epidemiological studies?
Douxfils, J. (Speaker)
1 May 2024Activity: Talk or presentation types › Invited talk
-
DOACs and Reversal Agents
Douxfils, J. (Speaker)
10 Apr 2024Activity: Talk or presentation types › Invited talk
-
Thromboses associées aux contraceptifs hormonaux combinés: évaluation du risque et suivi thérapeutique par un nouveau test, le nAPCr
Douxfils, J. (Speaker)
18 Apr 2024Activity: Talk or presentation types › Invited talk
-
Cardiovascular safety: the point of view of the veins
Douxfils, J. (Speaker)
8 Mar 2024Activity: Talk or presentation types › Invited talk
-
Innovative biomarkers in sepsis
Douxfils, J. (Speaker)
28 Mar 2024Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
16 Mar 2024Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
22 Feb 2024Activity: Talk or presentation types › Invited talk
-
Hormones-induced Coagulopathies — Evaluation of the Prothrombotic State Using a Global Coagulation Assay
Douxfils, J. (Speaker)
25 Jan 2024Activity: Talk or presentation types › Invited talk
-
Impact of progestagen alone or associated with estrogen on the coagulation: A state of the art in 2023
Douxfils, J. (Speaker)
1 Dec 2023Activity: Talk or presentation types › Invited talk
-
Safety profile of E4 Recent advance and evidence
Douxfils, J. (Invited speaker)
7 Nov 2023Activity: Talk or presentation types › Invited talk
-
Safety profile of E4 Recent advance and evidence
Douxfils, J. (Speaker)
14 Nov 2023Activity: Talk or presentation types › Invited talk
-
Hemostasis parameters with estetrol/drospirenone - why APC resistance matters
Douxfils, J. (Speaker)
30 Nov 2023Activity: Talk or presentation types › Invited talk
-
Combined Hormonal Contraceptives - Induced Coagulopathies Evaluation of the Prothrombotic State Using a Global Coagulation Assay
Douxfils, J. (Speaker) & Morimont, L. (Speaker)
4 Oct 2023Activity: Talk or presentation types › Invited talk
-
Safety profile of E4: Recent advance and evidence
Douxfils, J. (Keynote speaker)
18 Sept 2023Activity: Talk or presentation types › Invited talk
-
Donesta Partner Meeting : Acquired APC resistance as a marker for VTE, how does the estrogens differ?
Douxfils, J. (Keynote speaker)
4 Sept 2023 → 8 Sept 2023Activity: Talk or presentation types › Invited talk
-
Aquired APC-resistance as a marker for VTE, how reliable?
Douxfils, J. (Invited speaker)
27 Aug 2023Activity: Talk or presentation types › Invited talk
-
Risque induit par les oestrogènes de synthèse en clinique
Douxfils, J. (Invited speaker)
8 Jun 2023Activity: Talk or presentation types › Invited talk
-
Évaluation du risque vasculaire des contraceptifs
Douxfils, J. (Invited speaker)
21 Jun 2023 → 23 Jun 2023Activity: Talk or presentation types › Invited talk
-
APC resistance as a marker of the risk of VTE in users of oral contraceptives. Practical usefulness for industry and for clinicians
Douxfils, J. (Invited speaker)
26 May 2023Activity: Talk or presentation types › Invited talk
-
Estétrol: une nouvelle ère dans la contraception
Douxfils, J. (Invited speaker)
11 Feb 2023Activity: Talk or presentation types › Invited talk
-
Thromboembolie veineuse et contraception orale: Quelle stratégie pour minimiser le risque?
Douxfils, J. (Invited speaker) & Morimont, L. (Speaker)
12 Jan 2023Activity: Talk or presentation types › Invited talk
-
Global coagulation assays in the future of laboratory diagnostics of hemostasis and thrombosis - Interplay between platelets and coagulation
Douxfils, J. (Keynote speaker)
24 Nov 2022Activity: Talk or presentation types › Invited talk
-
Hormonal contraception and the risk of venous thrombosis – facts and myths
Douxfils, J. (Speaker)
18 Nov 2022Activity: Talk or presentation types › Invited talk
-
Drug monitoring of direct oral anticoagulants: Key considerations and prespectives
Douxfils, J. (Speaker)
3 Nov 2022Activity: Talk or presentation types › Invited talk
-
Acquired APC resistance as a marker for VTE, how reliable?
Douxfils, J. (Speaker)
7 Oct 2022Activity: Talk or presentation types › Invited talk
-
Impact of E4 on hemostasis — Key messages to understand its unique safety profile
Douxfils, J. (Speaker)
13 Sept 2022Activity: Talk or presentation types › Invited talk
-
Beeak-out Medical: Hemostasis and update on the Post Authorization Safety Study
Douxfils, J. (Speaker) & Chatel, G. (Speaker)
13 Sept 2022Activity: Talk or presentation types › Invited talk
-
Method validation for haemostasis assays: Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women. An unmet clinical and regulatory need
Douxfils, J. (Speaker)
15 Sept 2022Activity: Talk or presentation types › Invited talk
-
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity
Douxfils, J. (Speaker)
4 Jul 2022Activity: Talk or presentation types › Invited talk
-
L’associazione Estetrolo/Drospirenone: approfondimento sui parametri ematocoagulativi | Why APC resistance matters?
Douxfils, J. (Speaker)
14 Jun 2022Activity: Talk or presentation types › Invited talk
-
Impact des traitements hormonaux sur l’hémostase et exploration biologique : développement et perspectives actuelles
Douxfils, J. (Speaker)
7 Jun 2022Activity: Talk or presentation types › Invited talk
-
Monitoring des anticoagulants: Artéfacts ou avantages - Anticoagulants directs oraux
Douxfils, J. (Speaker)
20 Jun 2022Activity: Talk or presentation types › Invited talk
-
Safety profile of E4: recent clinical evidence
Douxfils, J. (Speaker)
12 May 2022Activity: Talk or presentation types › Invited talk
-
Impact des traitements hormonaux sur l’hémostase et exploration biologique : développement et perspectives actuelles
Douxfils, J. (Speaker)
17 May 2022Activity: Talk or presentation types › Invited talk
-
10 ans de monitoring des anticoagulants oraux. Où en sommes-nous et où allons-nous?
Douxfils, J. (Speaker)
15 Mar 2022Activity: Talk or presentation types › Invited talk